| Literature DB >> 35687817 |
Guangchun Han1, Qing Deng2, Mario L Marques-Piubelli3, Enyu Dai1, Minghao Dang1, Man Chun John Ma2, Xubin Li2, Haopeng Yang2, Jared Henderson2, Olga Kudryashova4, Mark Meerson4, Sergey Isaev4, Nikita Kotlov4, Krystle J Nomie4, Alexander Bagaev4, Edwin R Parra5, Luisa M Solis Soto5, Simrit Parmar2, Fredrick B Hagemeister2, Sairah Ahmed2, Swaminathan P Iyer2, Felipe Samaniego2, Raphael Steiner2, Luis Fayad2, Hun Lee2, Nathan H Fowler2,4, Christopher R Flowers2, Paolo Strati2, Jason R Westin2, Sattva S Neelapu2, Loretta J Nastoupil2, Francisco Vega3, Linghua Wang1,6, Michael R Green1,2,6,7.
Abstract
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression. SIGNIFICANCE: We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell-intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression. See related commentary by Melnick, p. 374. This article is highlighted in the In This Issue feature, p. 369. ©2022 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Year: 2022 PMID: 35687817 DOI: 10.1158/2643-3230.BCD-21-0075
Source DB: PubMed Journal: Blood Cancer Discov ISSN: 2643-3230